-58%

est. 2Y upside i

HealthcareSeries A

Eyebot is an outcome-focused technology company on a mission to make vision care accessible to everyone, equally. Headquartered in Boston’s North End and backed by top investors and the National Science Foundation, their 90-second vision test kiosk is reshaping how vision care is delivered.

Rank

#368

Sector

Healthtech

Est. Liquidity

~5Y

Data Quality

Data: Medium

Eyebot presents a compelling opportunity in healthtech, leveraging innovative kiosk technology and AI for accessible vision care.

Last updated: March 10, 2026

Bull (35%)+350%

Eyebot leverages its strategic partnerships with Walmart, Sam's Club, and 1-800 Contacts to rapidly expand its kiosk footprint nationwide, exceeding 1 million annual tests and diversifying into early disease screening. This market leadership and expanded service offering drive revenue to $50M+ by 2028, justifying a $470M+ valuation at 9-10x revenue.

Base (35%)+75%

Eyebot continues to grow steadily within its existing retail partnerships, reaching 750,000 annual tests and generating $15M-$20M in prescription and partnership revenue by 2028. While facing increasing competition from traditional optical providers, its convenience and doctor-verified model maintain a strong niche, leading to an acquisition or next funding round at ~$190M.

Bear (30%)-75%

Regulatory challenges intensify, or a major optical incumbent launches a directly competing, well-funded kiosk solution, significantly slowing Eyebot's expansion and market penetration. Slower adoption and increased capital needs lead to a down round or distressed acquisition at ~$27M, severely impacting common stock value due to the existing preference stack.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

28%

Investors hold $30M in liquidation preferences, meaning in an exit at or below the current $107M valuation, they would be paid first, significantly impacting common stock returns.

Dilution Risk

high

As a Series A company, Eyebot will likely undergo multiple additional funding rounds, each introducing further dilution to existing equity holders.

Secondary Liquidity

limited

While a secondary market valuation exists, current market activity for Eyebot stock is low with no reported buyers or sellers, indicating limited liquidity for employees.

Engineering — 3 roles

Compliance — 1 role

Operations — 1 role

View all 6 open roles at Eyebot →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Eyebot's data — designed to show you've done your homework.

  • 1

    “Given the pilot programs with Walmart and Sam's Club, and the partnership with 1-800 Contacts/The Framery, how is Eyebot strategically thinking about balancing direct-to-consumer growth through its kiosks versus deepening these B2B partnerships, especially if major optical chains like Luxottica decide to develop their own competing solutions?”

  • 2

    “With a projection of half a million annual vision tests, what are the key metrics the company is tracking to convert these free tests into paid prescriptions and maximize revenue from its hybrid model, particularly regarding the $20 prescription fee and retailer partnerships?”

  • 3

    “As a Series A company with a $107M valuation and $30M in total funding, how does Eyebot plan to manage future dilution for employees through subsequent funding rounds, and what is the anticipated timeline for a potential liquidity event, such as an acquisition or IPO?”

Community

Valuation Sentiment

Our model estimates -58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.